Skip to content
TriangleGet started
← Full study record

NCT00866047 · OUTCOME

Area Under the Curve

A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma · Source last updated 2017-03-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
GEOMETRIC_MEAN
Unit
day * microgram/mL
Interval / dispersion
Geometric Coefficient of Variation
Time frame
3 weeks

What was measured

Area under the serum concentration-time curve from time 0 to 21 days following the first dose of brentuximab vedotin

Analysis population: All participants who received treatment

Groups in this outcome

Brentuximab Vedotin

Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Brentuximab Vedotin58

Reported measurements

Source class 1
Values in day * microgram/mL · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Brentuximab Vedotin9869Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        69
        value
        98
denoms
  1. counts
    1. group Id
      OG000
      value
      58
    units
    Participants
description
Area under the serum concentration-time curve from time 0 to 21 days following the first dose of brentuximab vedotin
dispersion Type
Geometric Coefficient of Variation
groups
  1. description
    Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
    id
    OG000
    title
    Brentuximab Vedotin
param Type
GEOMETRIC_MEAN
population Description
All participants who received treatment
reporting Status
POSTED
time Frame
3 weeks
title
Area Under the Curve
type
SECONDARY
unit Of Measure
day * microgram/mL

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice